Earth Science Tech, Inc. Presents at SeeThruEquity Microcap Investor’s 6th Annual Conference in New York June 1st

May 25, 2017 12:15 pm UTC| Business

Hollywood, May 25, 2017 -- Earth Science Tech, Inc. (OTCPINK: ETST), an innovative biotech company focused on cannabis CBD-based (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals,...

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017 12:10 pm UTC| Business

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical...

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017 12:10 pm UTC| Business

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical...

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017 12:10 pm UTC| Business

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical...

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017 12:10 pm UTC| Business

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical...

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 25, 2017 12:10 pm UTC| Business

Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in Ongoing Phase 1/2 Clinical...

Nokia and Frontier Communications deploy G.fast technology to expand gigabit ultra-broadband access across Connecticut

May 25, 2017 12:09 pm UTC| Business

Nokia G.fast technology enables Frontier to quickly roll out fiber-like speeds to customers living in apartment buildings and deliver new IPTV and data service packages Norwalk, US - Nokia and Frontier Communications...